Trust Signals
Key Takeaways
- Hexarelin is a six-amino-acid GHSR-1a agonist with a molecular weight of 887.05 g/mol. It produces measurable GH pulses in humans at doses around 1 to 2 mcg/kg IV, confirmed in multiple small clinical studies.
- It raises cortisol and prolactin more than any other GHRP in its class. This is a documented pharmacological property, not a rare adverse event.
- Receptor desensitization with hexarelin is faster and more pronounced than with ipamorelin or GHRP-2, limiting practical continuous-use windows.
- A legitimate COA requires HPLC purity of at least 98% plus mass spectrometry confirmation at 887.05 g/mol. HPLC alone is insufficient to verify correct sequence.
- Cardioprotective effects demonstrated in rodent models via CD36 signaling have not been replicated in human RCTs. That mechanism is real but not clinically proven.
What Is Hexarelin and Should You Buy It?
If you want to buy hexarelin for GH secretagogue research, it is a potent but high-compromise option: it produces the largest acute GH pulse in its peptide class, but it desensitizes the pituitary faster than competitors, and it reliably raises cortisol and prolactin in human subjects. For most ongoing research protocols, ipamorelin offers a cleaner hormonal profile. Hexarelin earns its place in short-cycle or cardiac-mechanism research.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- Mechanism with Specific Numbers
- Evidence Ledger
- What Most Pages Get Wrong About Hexarelin
- What Are the Real Side Effects?
- Hexarelin vs. GHRP-6 vs. Ipamorelin: Honest Head-to-Head
- Dosing Table and Reconstitution Math
- Stability, Storage, and the Chemistry Behind the Rules
- Label and COA Literacy: How to Judge What You Are Buying
- Legal and Anti-Doping Status
- FAQ
- Sources
How Does Hexarelin Actually Work? Mechanism with Specific Numbers
Hexarelin (His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2) is a synthetic analog of GHRP-6 with a D-tryptophan residue methylated at position 2. That modification increases GHSR-1a binding affinity relative to GHRP-6 and confers partial resistance to peptidase cleavage, extending its functional half-life modestly in circulation compared to the parent compound.
Two receptor targets matter:
- GHSR-1a (growth hormone secretagogue receptor): Hexarelin is among the highest-affinity GHRP-class agonists at this receptor. Activation triggers a phospholipase C and inositol triphosphate cascade inside pituitary somatotrophs, mobilizing intracellular calcium and driving GH exocytosis. It also amplifies GHRH-driven pulses, so co-administration with a GHRH analog (CJC-1295, sermorelin) produces a supra-additive GH response in human studies.
- CD36 (scavenger receptor): Hexarelin binds CD36 independently of GHSR-1a. Rodent studies by Demers and colleagues demonstrated that this interaction mediates cardioprotective signaling, reducing ischemia-reperfusion injury in isolated rat hearts. This effect persisted in GH-deficient animals, confirming it is GH-independent. What that does NOT prove: the same protection occurs in human coronary disease at subcutaneous research doses.
The desensitization problem is also receptor-level. GHSR-1a undergoes rapid beta-arrestin-mediated internalization following sustained agonist exposure. Human data from Laron et al. and others showed that repeated hexarelin injections produced progressively attenuated GH peaks within days, a phenomenon less prominent with ipamorelin because ipamorelin has lower intrinsic efficacy at the receptor and drives less internalization per dose.
Evidence Ledger: What Is Actually Proven?
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| Hexarelin stimulates GH release in healthy humans | Multiple small human trials (IV/SC dosing, n = 8 to 20 per study) | Positive, dose-dependent | High |
| Hexarelin raises cortisol and prolactin in humans | Human trials (repeated observation) | Positive (unwanted elevation) | High |
| Pituitary desensitization with repeated dosing | Human pharmacodynamic studies | Attenuated response over time | High |
| Cardioprotection via CD36 in rodent ischemia models | Animal (rodent, in vitro) | Positive in animal models | Moderate (animal only) |
| Improved body composition (lean mass gain) in humans | Indirect inference from GH elevation; no dedicated RCT | Plausible but unproven | Low |
| Anti-aging or longevity benefit | Mechanism only; no human data | Speculative | Very Low |
| Superior to recombinant GH for GH deficiency treatment | Not studied in an RCT to this standard | No comparison data | Very Low |
What Most Pages Get Wrong About Hexarelin
Most hexarelin pages for sale present the CD36 cardioprotection finding as if it translates directly to human benefit at subcutaneous research doses. It does not. The rodent data used isolated perfused hearts and injected hexarelin at precise concentrations directly into the system. Whether subcutaneous dosing in a living human produces cardiac tissue concentrations anywhere near those used experimentally is unknown. The mechanism is real. The human clinical translation is not established.
The second common omission is the cortisol and prolactin signal. Medspa content routinely presents hexarelin as a "clean" GH stimulator. It is not. Peptides such as ipamorelin were specifically engineered to avoid the ACTH/cortisol axis activity that hexarelin and GHRP-6 trigger. If a researcher is studying GH secretagogue effects in isolation without confounding stress-hormone elevation, hexarelin is the wrong tool. This matters for study design and for anyone whose research involves adrenal or pituitary axis interpretation.
Third: purity degradation in transit. Lyophilized hexarelin is more stable than many reconstituted peptides, but suppliers who ship without cold packs or who store product at room temperature for months before sale deliver a lower-activity product even when the label reads "99% purity." A COA from time of synthesis is not the same as purity at time of delivery.
What Are the Documented Side Effects?
From human clinical study data, the following effects have been observed:
- Cortisol elevation: Statistically significant increases documented in multiple human studies following both IV and subcutaneous administration.
- Prolactin elevation: Observed reliably. Less pronounced than cortisol, but consistent across studies.
- ACTH increase: Documented alongside cortisol, suggesting hypothalamic-pituitary-adrenal axis activation, not just direct adrenal effect.
- Transient hunger: Present but generally less intense than GHRP-6's ghrelin-pathway-driven hunger, because hexarelin's affinity profile at the ghrelin receptor differs slightly from GHRP-6.
- Water retention: Expected consequence of any GH elevation; not unique to hexarelin.
- Injection site discomfort: Reported anecdotally; consistent with subcutaneous peptide injection generally.
Hexarelin vs. GHRP-6 vs. Ipamorelin: Honest Head-to-Head
| Attribute | Hexarelin | GHRP-6 | Ipamorelin |
|---|---|---|---|
| GHSR-1a potency (relative binding) | Highest in class | Moderate | Moderate to high |
| Acute GH pulse magnitude | Largest | Large | Moderate, consistent |
| Cortisol/Prolactin elevation | Yes, documented in humans | Yes, notable | Minimal, considered selective |
| Hunger side effect | Moderate | Strong (ghrelin pathway) | Minimal |
| Desensitization speed | Fast | Moderate | Slowest in class |
| CD36 / cardiac mechanism data | Yes (animal) | No | No |
| Human RCT body composition data | No | No | No |
| Best use case in research | Acute GH pulse studies, cardiac mechanism studies | Appetite/GH interaction studies | Sustained GH axis stimulation protocols |
| Hexarelin loses here | Ongoing GH protocols: ipamorelin wins on selectivity, consistency, and side effect profile. Hexarelin is not the default choice for most research designs. | ||
Dosing Table and Reconstitution Math
Human clinical study doses for GH stimulation testing used approximately 1 to 2 mcg per kg body weight given intravenously. Subcutaneous research protocols cited in the literature typically reference 100 mcg per injection administered one to three times daily, with longer intervals associated with less desensitization. Doses above roughly 200 mcg per injection have shown diminishing GH returns in documented human pharmacodynamic work.
| Vial Size | Reconstitution Volume (Bacteriostatic Water) | Resulting Concentration | Volume per 100 mcg Dose |
|---|---|---|---|
| 2 mg (2000 mcg) | 2 mL | 1000 mcg/mL | 0.10 mL (10 units on U100 syringe) |
| 2 mg (2000 mcg) | 4 mL | 500 mcg/mL | 0.20 mL (20 units on U100 syringe) |
| 5 mg (5000 mcg) | 5 mL | 1000 mcg/mL | 0.10 mL (10 units on U100 syringe) |
Reconstitution rule: Inject bacteriostatic water down the side of the vial slowly. Do not shake. Swirl gently until the lyophilized cake dissolves completely. A clear or faintly cloudy solution is normal. Visible particulates or a yellow color indicate degradation or contamination; discard the vial.
Stability, Storage, and the Chemistry Behind the Rules
Hexarelin in lyophilized form is relatively stable because removing water eliminates the primary hydrolysis pathway that cleaves peptide bonds. However, two degradation routes remain relevant even in powder form:
- Oxidation of tryptophan residues: Hexarelin contains two tryptophan residues (Trp at position 4, D-2-MeTrp at position 2). Tryptophan side chains are susceptible to oxidation by oxygen and light, producing kynurenine and oxolactone derivatives that are both inactive and potentially immunogenic. This is why opaque, sealed vials and refrigerated storage matter: not convention, but direct protection of the indole ring system. Exposure to UV light accelerates this reaction even in lyophilized powder.
- Aggregation after reconstitution: Once in solution, hexarelin peptide chains can associate non-covalently into oligomers, particularly with repeated freeze-thaw cycles or at concentrations above the saturation point for the formulation. Aggregated peptide is inactive and may be immunogenic. Bacteriostatic water (containing 0.9% benzyl alcohol) retards microbial growth but does not prevent peptide aggregation. Use reconstituted vials within 28 days refrigerated, and never freeze a reconstituted vial.
Rule summary: lyophilized, store at 2 to 8 degrees C, away from light, use within 24 months of synthesis. Reconstituted, refrigerate, use within 28 days, never freeze.
Label and COA Literacy: How to Judge What You Are Buying
This is the highest-value section on this page because it is what most hexarelin for sale pages omit entirely.
What a legitimate COA must contain:
- HPLC purity of at least 98% (some suppliers cite 95%, which is commercially acceptable but lower grade for research use)
- Mass spectrometry (MS) result confirming molecular weight at 887.05 g/mol, corresponding to the correct sequence. An HPLC chromatogram alone cannot confirm sequence identity. A truncated or otherwise incorrect analog may elute at a similar retention time and appear to pass HPLC while being a different and less active compound. MS confirmation is the only reliable way to verify the correct molecular species is present.
- Endotoxin (LAL) test result below 1 EU/mg. Bacterial endotoxin contamination from the synthesis process is a real risk in peptides manufactured at lower-grade facilities and can cause fever, inflammation, and systemic immune response upon injection.
- Lot number and synthesis date, not just a generic "batch" label, so you can correlate the COA to the actual vial shipped.
Red flags:
- COA without MS confirmation
- COA dated more than 18 months before your order (may not reflect current batch)
- Supplier who cannot provide endotoxin results
- Vials with no lot number or that arrive without cold-chain packaging for reconstituted products
- Pricing significantly below market rate, which often reflects lower-purity synthesis or inadequate quality control steps
Legal and Anti-Doping Status
In the United States, hexarelin is not approved by the FDA for any therapeutic indication. It is not a scheduled controlled substance under the Controlled Substances Act. It is sold legally by research chemical suppliers as a laboratory research compound, not for human consumption or clinical use.
WADA (World Anti-Doping Agency) lists hexarelin in its Prohibited List under Section 2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), specifically as a growth hormone secretagogue. Athletes subject to WADA-compliant testing who use hexarelin face a doping violation if detected in a urine or blood sample. Detection windows for peptides in anti-doping testing are compound-specific and not publicly standardized for hexarelin, but any use in a tested athlete carries meaningful regulatory risk.
FAQ
What is hexarelin and how does it work?
Hexarelin is a synthetic hexapeptide (His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2) that acts as an agonist at the growth hormone secretagogue receptor (GHSR-1a) and also binds the CD36 scavenger receptor. It stimulates GH release from the pituitary and has demonstrated cardioprotective signaling independent of GH in animal studies.
What is the research dosing range for hexarelin?
Human clinical studies used intravenous doses of roughly 1 to 2 mcg per kg body weight to assess GH pulse. Research protocols for subcutaneous use in investigational settings typically cite 100 to 200 mcg per injection. Doses above 2 mcg/kg IV produced a blunted response in at least one study due to rapid receptor desensitization.
Does hexarelin cause more desensitization than other GHRPs?
Yes. Hexarelin is the most potent GHSR-1a agonist in its class but also produces the fastest pituitary desensitization with continuous use. Studies in humans showed attenuated GH responses after repeated dosing cycles, more pronounced than seen with GHRP-2 or ipamorelin at equivalent schedules.
Does hexarelin raise cortisol or prolactin?
Yes. Multiple human trials documented statistically significant increases in cortisol and prolactin following hexarelin administration, an effect not seen to the same degree with ipamorelin. This is a genuine clinical distinction, not a marketing claim.
Is hexarelin legal to buy?
In the United States, hexarelin is not FDA-approved and is not a scheduled controlled substance. It is sold by research chemical suppliers for laboratory use only. It is on the WADA prohibited list under peptide hormones, meaning athletes subject to testing face a doping violation if detected.
How do I evaluate hexarelin purity from a supplier?
Request a Certificate of Analysis showing HPLC purity of at least 98%, mass spectrometry confirming the correct molecular weight of 887.05 g/mol, and endotoxin testing below 1 EU/mg. A COA without MS confirmation is insufficient because HPLC alone cannot distinguish a correctly sequenced peptide from a truncated or otherwise incorrect analog at a similar retention time.
How should hexarelin be stored after reconstitution?
Lyophilized hexarelin is stable at room temperature for shipping but should be stored at 4 degrees Celsius (refrigerated) long term. After reconstitution with bacteriostatic water, store at 4 degrees C and use within 28 to 30 days. Freeze-thaw cycling accelerates aggregation and should be avoided.
What are the known side effects of hexarelin?
Documented effects from human studies include elevated cortisol, prolactin, and ACTH. Injection site reactions, transient hunger (less prominent than GHRP-6), and water retention from GH elevation are reported. Cardiac effects observed in animal models have not been replicated in human safety trials at low research doses.
How does hexarelin compare to ipamorelin?
Hexarelin produces a larger acute GH pulse but raises cortisol and prolactin, desensitizes faster, and has a shorter effective use window. Ipamorelin is more selective, does not meaningfully raise cortisol or prolactin, and maintains GH release more consistently with repeated dosing. Most researchers prefer ipamorelin for ongoing protocols.
Can hexarelin be used for cardiac research purposes?
Animal studies, primarily in rodent models, showed hexarelin reduced infarct size and improved post-ischemic cardiac function via CD36 receptor binding. These findings are interesting mechanistically but have not been validated in human RCTs. Any cardiac application in humans remains speculative at this time.
What does a degraded hexarelin vial look like?
A degraded vial may show visible particulates or cloudiness after reconstitution, a yellow or amber tint in solution (lyophilized hexarelin should reconstitute to clear or very slightly off-white), or a loss of the characteristic cake-like lyophilized appearance before reconstitution. Any of these signs indicate the product should not be used.
Sources
- Ghigo E, Arvat E, Muccioli G, Camanni F. "Growth hormone-releasing peptides." Eur J Endocrinol. 1997;136(5):445-460. PubMed PMID: 9186268.
- Arvat E, Ramunni J, Giordano R, et al. "The GH, prolactin, ACTH and cortisol responses to hexarelin, a synthetic hexapeptide, undergo different age-related variations." Eur J Endocrinol. 1997;137(3):288-295. PubMed PMID: 9330595.
- Demers A, McNicoll N, Febbraio M, et al. "Identification of the growth hormone-releasing peptide binding site in CD36: a photoaffinity cross-linking study." Biochem J. 2004;382(Pt 2):417-424. PMC548054.
- Bisi G, Podio V, Valetto MR, et al. "Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans." J Endocrinol Invest. 1999;22(4):266-272. PubMed PMID: 10342350.
- Laron Z, Frenkel J, Deghenghi R, et al. "Intranasal administration of the GHRP hexarelin accelerates growth in short children." Clin Endocrinol (Oxf). 1995;43(5):631-635. PubMed PMID: 8548944.
- Muccioli G, Papotti M, Locatelli V, Ghigo E, Deghenghi R. "Binding of 125I-labeled ghrelin to membranes from human hypothalamus and pituitary gland." J Endocrinol Invest. 2001;24(3):RC7-9. PubMed PMID: 11314752.
- WADA Prohibited List 2024. World Anti-Doping Agency. https://www.wada-ama.org/en/prohibited-list. Accessed 2026-05-29.
- Thidestrom A, Johansson AG, Wide L, Ljunghall S, Homb N, Ljunggren O. "Effects of short-term administration of hexarelin and GHRH alone and in combination in man." Clin Endocrinol (Oxf). 1999;51(1):57-62. PubMed PMID: 10468971.
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. "Stability of protein pharmaceuticals: an update." Pharm Res. 2010;27(4):544-575. PubMed PMID: 20143256.